T1	Participants 125 183	'high risk' pre- and postmenopausal breast cancer patients
T2	Participants 625 748	pre- (n = 547) and postmenopausal (n = 679) patients, respectively, with node positive disease or a tumour diameter > 30 mm
T3	Participants 1795 1814	high-risk patients,
